Benzinga | Dec 11, 2020 11:09AM EST

Karyopharma Reports National Comprehensive Cancer Network Adds 3 XPOVIO Treatment Regimens To Clinical Practice Guidelines In Oncology For Multiple Myeloma

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network(r) (NCCN) added three different XPOVIO(r) (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) for previously treated multiple myeloma. The XPOVIO regimens added to the NCCN guidelines, include: (i) selinexor / bortezomib / dexamethasone (once-weekly) (SVd); (ii) selinexor / daratumumab / dexamethasone (SDd); and (iii) selinexor / pomalidomide / dexamethasone (SPd), which is an all-oral treatment regimen. Importantly, the once weekly SVd regimen received a Category 1 recommendation, which represents the highest designation assigned by NCCN indicating the recommendation is based upon high-level evidence and that there is uniform NCCN consensus that the intervention is appropriate.

"We are honored to have XPOVIO receive this important recognition through its addition to the NCCN Guidelines," said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. "The NCCN Guidelines are utilized by healthcare providers across the country to inform optimal treatment decision making. The inclusion of three different XPOVIO combination regimens into these guidelines further validates the importance XPOVIO may have in the future multiple myeloma treatment landscape."

The NCCN is a not-for-profit alliance of 30 leading cancer centers devoted to patient care, research, and education. The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions that currently apply to 97% of cancers affecting patients in the U.S and are intended to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that will most likely lead to optimal outcomes.

Karyopharm's supplemental New Drug Application requesting approval for XPOVIO as a treatment for patients with multiple myeloma who have received one prior line of therapy has been assigned an FDA action date of March 19, 2021 under the Prescription Drug User-Fee Act.